{"name":"Viridian Therapeutics, Inc.","slug":"viridian-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Veligrotug (VRDN-001)","genericName":"Veligrotug (VRDN-001)","slug":"veligrotug-vrdn-001","indication":"Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"VRDN-003","genericName":"VRDN-003","slug":"vrdn-003","indication":"Graves' disease (hyperthyroidism)","status":"phase_3"}]}],"pipeline":[{"name":"Veligrotug (VRDN-001)","genericName":"Veligrotug (VRDN-001)","slug":"veligrotug-vrdn-001","phase":"phase_3","mechanism":"Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides.","indications":["Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk"],"catalyst":""},{"name":"VRDN-003","genericName":"VRDN-003","slug":"vrdn-003","phase":"phase_3","mechanism":"VRDN-003 is a monoclonal antibody that targets and inhibits thyroid-stimulating immunoglobulin (TSI) to reduce autoimmune thyroid activation in Graves' disease.","indications":["Graves' disease (hyperthyroidism)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNaGNCZXUxWERHZXhLYVMxOFBMa2MzcE10dXRCeUpfMTZwcEJOYzZ5ZWdtVGRwcVpRU1Y1cUNnY0tFWmFVZXY2VldwQjctSWVnUjF2N08wN21YZVdCNFFNamRRVGFydEFUT0dKN3BCWlE2RnBaSHphZ0RTaFNpWHlWYmZpblM3WmxkZFVNNlF5R0dPMTk5SFkwZE94ZVNjTHp4alhXQ0dvaDZrU21NTTZYOFp3amdzMV9wYWhLamNHMHBGQ2p4bmNWdUFESWNTcVlMZURuVTNOS3FLQm4wQ2xlbEFwU3pjRWEydWpKSERjUGFYX1gwY1RONmFIaGJ0eDZ2ZVItVnRzRXhDZDdOU1JDM1JaRjNJX1ZJcms0LUtwOWo?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOMUcwSDU2R0VWd0Q3MWRoY25QM3ByWkctQThhWVZWTzE1cm1weEJkd25OZlVKdWc1eXhqZkItdHZuRExFbEI0TklTcnhsR0RZZHJUQVlrellfR3B4b3FyZ3NCSTl0SVU0dDY5QzVyc3JnX2VQc0JfTElESkliWGNDQjMtSzlMZ21ibUNkaks0aUtZa1REQmFqbmJZRy1OMThmTzZSZkx1Um1Kdm5oNTdTcXJjdFYzMFVHcVg4UnlWVE0yZlBCWW5QR1g4NExsSzFtWnk4UjAzckdxT0IyamhRbnpHTXdKR1R2UHViSTR6UGx4bjlHZGMtWGNDOTd0SDdKbnVQeldZTDRFUnp5Ump0MUJxcDhDNktDcXc?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQemNQUFNlMzB6UjFCdGxMUDVZSll5akYyU2ZLNjAyd1lnRkFOU2NDZ0RFNGw4V095dWtfLUpoNDBrQXl1ekY5blNsZUliZzVaZl92ZEFWTEl6Y1U4OWFCMW5SVlhRRVFVUlk1TFdlMlk4bmllQ1cwb1hkLUZpakFpNl9VMUN3MWp4TTJRWFkzU3E?oc=5","date":"2026-04-06","type":"trial","source":"Barron's","summary":"Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. - Barron's","headline":"Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE54NHJyc2FUNFZ5djVsalZiWERsYWVEeWpPNU5WdE5NWm5wU2ZXb3QzN0w0U3YwN3k5YlM1VW45TENxYW1RRkNiSThOVThXVGtFZ0E?oc=5","date":"2026-04-06","type":"pipeline","source":"Yahoo Finance UK","summary":"Viridian Therapeutics, Inc. (VRDN) stock price, news, quote and history - Yahoo Finance UK","headline":"Viridian Therapeutics, Inc. (VRDN) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOLVp3UE1SUjVFeEg2YVR5X2NvS2JHY2lCdFdmUmdkU2hOTXQ4eGZjaW9LOERPbEM5eC1SSkY2OVFHYUlxYUh2Q21kWGZ4SXpFY2p2M0puQzBXaFFUcG5Vbk10SmlRSXUwN1I2aWtuZTJrdUVYS1NYeWRqX1lGd2JIOHF0VWlmMVdKYVNpRjBKelpQbGVfcWJjSHUteWVFWnduYzFqeGo1amFzSmJzTFdfaUJQUXVZNmdtc2xkSnlaVDIzVDVPR2tjek1Zcw?oc=5","date":"2026-03-30","type":"trial","source":"Reuters","summary":"Viridian sinks as eye disease drug disappoints on efficacy despite trial success - Reuters","headline":"Viridian sinks as eye disease drug disappoints on efficacy despite trial success","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT2dySHEybks5UEIxQjU1ak1lY0dLZm5JRmlONWM1NzByc2RiSURvX3dnaGZuYVRpLTBfMzNFOTN0YnpkeXZXZzVGd2xoUU4xQWdoTExMOFJiVDJhMThtWElURXRoT29QUVFxampXb2RzeG5nTnliTk9PeVBJSXc4QnFtWTRuWTVrUTZ3T3l5T01UYmN4YUVSeFVjR0xDZENlTDRoRVNpUHVFZGc?oc=5","date":"2026-01-26","type":"pipeline","source":"seekingalpha.com","summary":"Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) - seekingalpha.com","headline":"Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOTHpRbmxlUGMwdENPMklJZl9zX2hMN1V5UXM1SW4zS3RqSDJkZEJpUGhLanprSnRUN1VvV0NNcktBUFpqcGFnZ0M0RzZoNUw4eEEtYnRxamhrc3ZpTGg1eDZiWVNSQWlzV0VvRkluY2lOT01aMDVlR2pGRGN1N2hDdTZNSDFhSDRjUHZMcF8xcTBWRkxTb2hkc1dKNll2OVc3YTQ3ZHQtcWpHZnNvaDVXRndOVQ?oc=5","date":"2026-01-06","type":"pipeline","source":"Business Wire","summary":"Viridian Therapeutics Prepares for Transformational 2026 - Business Wire","headline":"Viridian Therapeutics Prepares for Transformational 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQX3JNWHBJeEN3MHBLVjFMWEp5X2hsRnEtc1RyemY2dmZWbzVLbVlNLXp3Q2lFVEVLTjhRQ3lXTVUzcklSZll3YVFMNEVyVmtkd0gzVHpySlpWMWJkdVJrMWhzTVBDZUtTcGpFVHY0OVlqMDd6V01Ec2FucThOWDNDZXpTNEdBRkdFNWRadkFoSEJTMHVTLUdSQkR4TmptTFRMdVhtRDdLY0pYbFFndnZYVThKTzdteTBZSWV6TldoWl9QaVg0Wkd4UzhwM1lYcE9rNEZaUHBfY09TRFBOR3NkV0VqZTBuRmt3M3VjY2NLQ0lmZWZNdi1HM0RLSjU1TTlOQVJXNlFicGxpX2M?oc=5","date":"2025-12-22","type":"pipeline","source":"Business Wire","summary":"Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire","headline":"Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNeEpOT3BVWEZpM3c4c21wVjRac2hiNHBlNWdOZjRxNXloX3FqRmVSUk16cDJZZEJMTUd3eE1XLTVqVE0zSmdiOGtlV1JudlRMT19PeFBNajkzTmd3SU5lNWVWWUdaYmpQZzVhaExGSTg4N2FITUZibFhWa0VlS281MVhCazJFN2NUalE3LWdyZXJtSFhtdUJz?oc=5","date":"2025-11-06","type":"pipeline","source":"seekingalpha.com","summary":"Viridian Therapeutics Is Ready For An Eventful 2026 (NASDAQ:VRDN) - seekingalpha.com","headline":"Viridian Therapeutics Is Ready For An Eventful 2026 (NASDAQ:VRDN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxObkpSQ005WUFFMG5lMTlBS2FvOTVYNVdvMlhJSUlGV0ZPSTUweUtYT25TMkpSRVR4VjlmMTVndkRlTEhJZE03MmF1RlpmUDVYRW9kTUc1MnlXejY1TFlBLU5DZnBaWWxWSFFWUFhsT0hzRGFDUE9WRG0zc0FHYXdOT2E4VXVlOGZmVTRCVkRQcFZNc0c2dHBYN1IxbWZxZHl2dnlncWJHTVliYXkySmdwRXEwNjFhTy1jOVZ2clVtWTZ5Z1V2TzVPenNEWW5Wd0hTd1FVQ3c4Zi1LaXBwMkprN2lHWm9ZOTljRVVmbQ?oc=5","date":"2025-10-21","type":"pipeline","source":"Business Wire","summary":"Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire","headline":"Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-30","type":"deal","source":"BioSpace","summary":"Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and ","headline":"Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbXNQbUR5OGVBRHV3UnhZNWlLdGliVThyWlJ2TmQ1dzNUVjIxNFQ2ZGpHRzV3cVU0ZjF4aC1OZjQ5MWxmV0JJUkwyVC1LSGFWY09VMnItWkMyVXFFc0dxWERkcXBGc08wUml0Rk0zTXE2VnhHWWNSbkxxYXVZSmNVWGxWTWJtX2o1YkJuR0d1X2FkcWZRaGVoSU14MHpyRXdRVGp6U0dnaVFTZw?oc=5","date":"2025-07-30","type":"pipeline","source":"Fierce Biotech","summary":"Kissei pays Viridian $70M to challenge Amgen for Japanese eye disease market - Fierce Biotech","headline":"Kissei pays Viridian $70M to challenge Amgen for Japanese eye disease market","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}